Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers

被引:104
作者
Polley, Mei-Yin C. [1 ]
Freidlin, Boris [1 ]
Korn, Edward L. [1 ]
Conley, Barbara A. [2 ]
Abrams, Jeffrey S. [3 ]
McShane, Lisa M. [1 ]
机构
[1] NCI, Biometr Res Branch, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA
[2] NCI, Canc Diag Program, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA
[3] NCI, Canc Treatment & Evaluat Program, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 22期
关键词
CELL LUNG-CANCER; RANDOMIZED PHASE-III; ADJUVANT TEMOZOLOMIDE; MAINTENANCE THERAPY; DESIGN; CETUXIMAB; EGFR; CHEMOTHERAPY; RADIOTHERAPY; CONCOMITANT;
D O I
10.1093/jnci/djt282
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Predictive biomarkers to guide therapy for cancer patients are a cornerstone of precision medicine. Discussed herein are considerations regarding the design and interpretation of such predictive biomarker studies. These considerations are important for both planning and interpreting prospective studies and for using specimens collected from completed randomized clinical trials. Specific issues addressed are differentiation between qualitative and quantitative predictive effects, challenges due to sample size requirements for predictive biomarker assessment, and consideration of additional factors relevant to clinical utility assessment, such as toxicity and cost of new therapies as well as costs and potential morbidities associated with routine use of biomarker-based tests.
引用
收藏
页码:1677 / 1683
页数:7
相关论文
共 28 条
[1]
[Anonymous], ASCO M
[2]
[Anonymous], EV CLIN VAL CLIN UT
[3]
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer [J].
Brugger, Wolfram ;
Triller, Nadja ;
Blasinska-Morawiec, Maria ;
Curescu, Stefan ;
Sakalauskas, Raimundas ;
Manikhas, Georgy Moiseevich ;
Mazieres, Julien ;
Whittom, Renaud ;
Ward, Carol ;
Mayne, Karen ;
Trunzer, Kerstin ;
Cappuzzo, Federico .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4113-4120
[4]
Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation [J].
Freidlin, Boris ;
Sun, Zhuoxin ;
Gray, Robert ;
Korn, Edward L. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) :3158-3161
[5]
Randomized Clinical Trials With Biomarkers: Design Issues [J].
Freidlin, Boris ;
McShane, Lisa M. ;
Korn, Edward L. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (03) :152-160
[6]
MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[7]
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer [J].
Henry, N. Lynn ;
Hayes, Daniel F. .
ONCOLOGIST, 2006, 11 (06) :541-552
[8]
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect [J].
Jiang, Wenyu ;
Freidlin, Boris ;
Simon, Richard .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (13) :1036-1043
[9]
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer [J].
Khambata-Ford, Shirin ;
Harbison, Christopher T. ;
Hart, Lowell L. ;
Awad, Melissa ;
Xu, Li-An ;
Horak, Christine E. ;
Dakhil, Shaker ;
Hermann, Robert C. ;
Lynch, Thomas J. ;
Weber, Martin R. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :918-927
[10]
Early termination of a two-stage study to develop and validate a panel of biomarkers [J].
Koopmeiners, Joseph S. ;
Vogel, Rachel Isaksson .
STATISTICS IN MEDICINE, 2013, 32 (06) :1027-1037